Clinical trials: Myeloma, Plasma-Cell
Acute Myeloid Leukemia, Precursor-cell Lymphoblastic Leukemia-Lymphoma
Prevention of Left Ventricular Dysfunction During Chemotherapy
The investigators' objective is to assess the efficacy of the combined treatment with enalapril and carvedilol in the prevention of left ventricular systolic dysfunction in patients with hematological malignancies submitted to…
- Conditions
- Acute Myeloid Leukemia, Precursor-cell Lymphoblastic Leukemia-Lymphoma, Lymphoid Neoplasm, Multiple Myeloma
- Trial name
- OVERCOME (NCT01110824)
- Testing
- Enalapril and carvedilol
- Where
- 2 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Hospital Clinic of Barcelona
Multiple Myeloma, Smoldering Multiple Myeloma
European Myeloma Network (EMN) Sample Project
This is an observational, non-interventional, multicenter study for the prospective collection, storage and analysis of patients' biological samples.
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Myeloma
- Trial name
- EMN36 (NCT06237803)
- Testing
- storage of biological samples
- Where
- 41 sites in Australia, Austria and 8 more
- Volunteers
- 6,000 people
- Sponsor
- European Myeloma Network B.V.
Myeloproliferative Disorders, Lymphoproliferative Disorders
In Vitro Drug Sensitivity Testing of Fresh Human Samples
Hematological malignancies gather several various pathologies included myeloproliferative disorders (as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML)) and lymphoproliferative disorders (as chronic lymphoid…
- Trial name
- ESAAC (NCT05001386)
- Testing
- Blood collection for the evaluation of the anti-drugs sensitivity
- Where
- 2 sites in France
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Multiple Myeloma
Digital Life Coaching for Myeloma Patients Undergoing Transplantation
This is the first study of digital life coaching (DLC) to engage patients during the peri-HCT period that is punctuated by intensive life changes.
- Trial name
- NCT04432818
- Testing
- Pack Health's digital life coaching (DLC)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Heart Failure, Multiple Myeloma
Prospective Observation of Cardiac Safety With Proteasome Inhibition
The purpose of this study is to better define and understand potential cardiac toxicities of proteasome inhibitors and to understand optimal management strategies to treat and prevent cardiovascular events.
- Trial name
- PROTECT (NCT02178579)
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Vanderbilt University Medical Center
Multiple Myeloma
Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
This is an open-label, phase 1 study to assess the safety, pharmacodynamics, and anti-myeloma effects of autologous T cells expressing BCMA (B-cell maturation antigen)-specific chimeric antigen receptors with tandem TCRζ and…
- Trial name
- NCT03549442
- Testing
- BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART BCMA or CART BCMA + huCART19
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma, Relapsed/Refractory
Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement
This is a phase 2 study to see how effective investigational drug, JNJ-42756493, is when given in combination with dexamethasone in two groups of patients with multiple myeloma (cancer of the plasma cells, a type of white blood…
- Trial name
- NCT02952573
- Testing
- JNJ-42756493, Dexamethasone
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Tacrolimus and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by donor stem cell transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00096096
- Testing
- mycophenolate mofetil, tacrolimus
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Refractory Multiple Myeloma
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as azacitidine and dexamethasone, work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01155583
- Testing
- azacitidine, lenalidomide, dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM)
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
This study is evaluating the safety, pharmacokinetic profile and efficacy of venetoclax under a once daily dosing schedule in Japanese participants with hematological malignancies.
- Conditions
- Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Trial name
- NCT02265731
- Testing
- azacitadine, venetoclax, rituximab / IDEC-C2B8
- Where
- 14 sites in Japan
- Volunteers
- 38 people
- Sponsor
- AbbVie
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma
This is a phase I clinical study to evaluate the safety and tolerability of C-4-29 in patients with relapsed or refractory multiple myeloma, and to obtain the maximum tolerated dose of C-4-29 and phase II Recommended dose.
- Trial name
- NCT04861480
- Testing
- C-4-29 Cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Newly Diagnosed Multiple Myeloma
Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation
The investigators will conduct randomized and controlled clinical studies in order to preliminarily explore the efficacy and safety of low-dose cyclophosphamide and lenalidomide in maintenance therapy for MM that is not suitable…
- Trial name
- NCT06324266
- Testing
- Cyclophosphamide, Lenalidomide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Jinling Hospital, China
Multiple Myeloma
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
This phase 2 study is designed to evaluate the safety and tolerability activity of TH-302 and dexamethasone with or without bortezomib or pomalidomide in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT01522872
- Testing
- TH-302, TH-302 and Dexamethasone, TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Threshold Pharmaceuticals
Multiple Myeloma
Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma
The purpose of this research is to study how helpful thalidomide is in controlling the myeloma disease and to study any side effect resulting from thalidomide.
- Trial name
- NCT00083577
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of Arkansas
Multiple Myeloma
Safety and Efficacy Assessments of Osalmid in Multiple Myeloma
This study aims to evaluate the safety and efficacy of a traditional cholagogue drug osalmid, 2-hydroxy-N-(4-hydroxyphenyl)-benzamide, in the treatment of multiple myeloma (MM).
- Trial name
- NCT03670173
- Testing
- Osalmid
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai 10th People's Hospital
Multiple Myeloma
A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life
Four monthly treatments with pegylated liposomal doxorubicin, thalidomide and dexamethasone for newly diagnosed myeloma patients as induction therapy prior to high dose chemotherapy and autologous stem cell transplant.
- Trial name
- NCT00222105
- Testing
- Doxil, Thalidomide, Dexamethasone
- Volunteers
- 25 people
- Sponsor
- University of Kansas Medical Center
Multiple Myeloma, Effects of Chemotherapy
Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation
This study compared two main different induction protocols used to treat myeloma eligible patients in Brazil. VCD against CTD.
- Trial name
- GBRAM003r (NCT03402295)
- Testing
- Bortezomib, cyclophosphamide, thalidomide, dexamethasone
- Volunteers
- 311 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Multiple Myeloma
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
- Trial name
- NCT05372354
- Testing
- CC-92480, Tazemetostat, BMS-986158
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
Hematologic Neoplasms
Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer
Umbilical cord blood is an important source of stem cells and can be used to treat blood and immune system disorders and certain types of cancer.
- Trial name
- NCT00312429
- Testing
- Stem Cell Transplantation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Duke University
Multiple Myeloma
A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate tolerability of the combination therapy of JNS002 and bortezomib in Japanese bortezomib-naive patients with multiple myeloma who have ever received at least 1 line of chemotherapy.
- Trial name
- NCT01371227
- Testing
- JNS002
- Where
- 2 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Janssen Pharmaceutical K.K.